There are currently no drugs approved in the European Union to treat the liver condition known as MASH, but a new trial of ...

Popular medications for obesity and diabetes have been linked to an increased risk of hair loss, particularly for women. Researchers and doctors weigh in.

Semaglutide, the active ingredient in popular drugs Ozempic and Wegovy, isn’t without its risks. A recent study has found ...

While both may be used in people with type 2 diabetes, Ozempic is approved by the FDA, but compounded semaglutide is not. Compounded drugs are custom-made medications that are mixed, combined ...

For example, a 2021 Wegovy trial with almost ... There are a few different semaglutide drugs. Here’s a quick rundown: Wegovy. Wegovy is a weekly injection FDA-approved for those with excess ...

A trial shows that semaglutide stops fat accumulation and liver fibrosis in a disease associated with metabolic dysfunction ...

The Food and Drug Administration (“FDA”) has removed semaglutide from its drug shortage list after the agency determined the current supply of ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide ... Ozempic or Mounjaro for example, from their local pharmacy. Starting last week, some compounding ...

Semaglutide belongs to a class of medications known as GLP-1 receptor agonists. Even when used correctly under doctor supervision, they come with potential side effects. And when patients have to ...

The treatments, which include medications like semaglutide, liraglutide and exenatide ... at an increased risk of cognitive decline, for example if they had a family history of the condition.

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide drugs — like Ozempic, Wegovy, and compounded semaglutide — can be a godsend for those with type 2 diabetes or obesity.